Actos, Pioglitazone
Actos, Pioglitazone Newswire

Actos, Pioglitazone Newswire

Comprehensive Real-Time News Feed for Actos, Pioglitazone (generic).

Results 1 - 20 of 241 in Actos, Pioglitazone (generic)

  1. Takeda completes post-marketing commitment and data submission for pioglitazone containing medicinesRead the original story w/Photo

    Friday | Medical News

    Takeda Pharmaceutical Company Limited today announced the completion of the study to fulfill the post-marketing commitment and submissions of data to regulatory authorities from the Pan European Multi-Database Bladder Cancer Risk Characterization Study , a large , multi-database retrospective matched cohort study, conducted in four European countries, for pioglitazone containing medicines, including ACTOS with up to 10 years of follow-up. Findings demonstrate that there is no association between the use of pioglitazone and the risk of bladder cancer, .

    Comment?

  2. Takeda Announces Completion Of The Pioglitazone Post-Marketing...Read the original story

    Wednesday Jul 29 | BioSpace

    Findings demonstrate that there is no association between the use of pioglitazone and the risk of bladder cancer, . These results are consistent with those of a 10-year, prospective cohort study, conducted by the ) and Division of Research at Kaiser Permanente Northern California , which demonstrated no increased risk of bladder cancer among patients ever exposed to pioglitazone .

    Comment?

  3. Global and Chinese Pioglitazone hydrochloride (CAS 112529-15-4)...Read the original story

    Thursday Jul 30 | PR-inside.com

    The 'Global and Chinese Pioglitazone hydrochloride Market, 2009-2019 Market Research Report' is a professional and in-depth study on the current state of the global Pioglitazone hydrochloride industry with a focus on the Chinese market. The report provides key statistics on the market status of the Pioglitazone hydrochloride manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

    Comment?

  4. High Blood Sugar May Boost Alzheimer's RiskRead the original story w/Photo

    Tuesday Jul 28 | MedicineNet

    Researchers found that insulin resistance -- higher-than-normal levels of blood sugar that often precede type 2 diabetes -- was related to poorer performance on memory tests taken by late-middle-age adults. "The findings are interesting because people with diabetes are at increased risk for developing Alzheimer's disease, but we are only now learning why they may be at increased risk," said lead researcher Barbara Bendlin, an assistant professor of medicine at the University of Wisconsin-Madison.

    Comment?

  5. Common Diabetes Med May Protect Against Parkinson's Disease, London...Read the original story

    Tuesday Jul 21 | BioSpace

    Diabetes drug may protect against Parkinson's disease A type of drug used to treat diabetes may reduce the risk of developing Parkinson's disease A type of drug used to treat diabetes may reduce the risk of developing Parkinson's disease, according to a new study published in PLOS Medicine. The research, led by the London School of Hygiene & Tropical Medicine, found that diabetes patients taking glitazone antidiabetes drugs had a 28% lower incidence of Parkinson's disease than people taking other treatments for diabetes who had never taken glitazones.

    Comment?

  6. Low-dose lithium lowers involuntary motor movements in mouse model of Parkinson's diseaseRead the original story w/Photo

    Monday Jul 27 | Medical News

    Low-dose lithium reduced involuntary motor movements - the troubling side effect of the medication most commonly used to treat Parkinson's disease - in a mouse model of the condition that is diagnosed in about 60,000 Americans each year. The third in a series of studies from the Andersen lab involving PD and low-dose lithium, the results add to mounting evidence that low-doses of the psychotropic drug could benefit patients suffering from the incurable, degenerative condition.

    Comment?

  7. Low-dose lithium reduces side effects from most common treatment for Parkinson's diseaseRead the original story w/Photo

    Monday Jul 27 | PhysOrg Weblog

    Immunohistochemistry for alpha-synuclein showing positive staining of an intraneural Lewy-body in the Substantia nigra in Parkinson's disease. Credit: Wikipedia Low-dose lithium reduced involuntary motor movements - the troubling side effect of the medication most commonly used to treat Parkinson's disease - in a mouse model of the condition that is diagnosed in about 60,000 Americans each year.

    Comment?

  8. Diabetes drug not linked to bladder cancer riskRead the original story

    Saturday Jul 25 | Newkerala.com

    A new study has quashed the claims that diabetes drug 'Actos' raise bladder cancer risk in users, suggesting that it is safer than previously thought. Contrary to smaller, prior studies suggesting that the drug might raise users' risk of bladder cancer, the large new study found no evidence for such an effect.

    Comment?

  9. Nonalcoholic fatty liver disease: a systematic review.Read the original story

    Thursday Jul 23 | CiteULike

    Nonalcoholic fatty liver disease and its subtype nonalcoholic steatohepatitis affect approximately 30% and 5%, respectively, of the US population. In patients with nonalcoholic steatohepatitis, half of deaths are due to cardiovascular disease and malignancy, yet awareness of this remains low.

    Comment?

  10. Study Refutes Notion That Diabetes Drug Actos Raises Bladder Cancer RiskRead the original story w/Photo

    Wednesday Jul 22 | MedicineNet

    Despite smaller, prior studies suggesting that the diabetes drug Actos might raise users' risk of bladder cancer , a large new study finds no evidence for such an effect. However, the study did find an association between the use of Actos and a rise in the risk of pancreatic cancer , although experts say it's too early to draw any conclusive link.

    Comment?

  11. Diabetes Drugs May Offer Hope for Parkinson's Disease TreatmentRead the original story w/Photo

    Wednesday Jul 22 | Time

    Researchers analyzed data on more than 160,000 diabetes patients in the U.K. and found that patients who took rosiglitazone or pioglitazone had a 28% lower chance of developing Parkinson's than their counterparts who took other diabetes medication, according to the study, published in the journal PLOS Medicine . The drugs were originally developed by GlaxoSmithKline and Takeda, respectively, but they are now off patent.

    Comment?

  12. Analyses finds no strong association between use of diabetes drug...Read the original story w/Photo

    Wednesday Jul 22 | Medical News Today

    Although some previous studies have suggested an increased risk of bladder cancer with use of the diabetes drug pioglitazone, analyses that included nearly 200,000 patients found no statistically significant increased risk, however a small increased risk could not be excluded, according to a study in JAMA . Additional analyses with another large group found that use of pioglitazone was associated with an increase in the risk of prostate and pancreatic cancer , although further investigation is needed to assess whether the associations are causal or due to other factors.

    Comment?

  13. Study shows glitazone antidiabetic drug may reduce risk of Parkinson's diseaseRead the original story w/Photo

    Wednesday Jul 22 | Medical News

    A type of drug used to treat diabetes may reduce the risk of developing Parkinson's disease, according to a new study published in PLOS Medicine. The research, led by the London School of Hygiene & Tropical Medicine, found that diabetes patients taking glitazone antidiabetes drugs had a 28% lower incidence of Parkinson's disease than people taking other treatments for diabetes who had never taken glitazones.

    Comment?

  14. Study examines link between use of diabetes drug pioglitazone and increased risk of bladder cancerRead the original story w/Photo

    Wednesday Jul 22 | Medical News

    Although some previous studies have suggested an increased risk of bladder cancer with use of the diabetes drug pioglitazone, analyses that included nearly 200,000 patients found no statistically significant increased risk, however a small increased risk could not be excluded, according to a study in the July 21 issue of JAMA . Assiamira Ferrara, M.D., Ph.D., of Kaiser Permanente Northern California, Oakland, and colleagues studied with several groups of persons with diabetes: a bladder cancer cohort that followed 193,099 persons until December 2012; 464 case patients and 464 matched controls were surveyed about additional confounders ; and a cohort analysis of 10 additional cancers included 236,507 persons and followed until June 2012.

    Comment?

  15. Class of diabetes medication associated with lower incidence of Parkinson's diseaseRead the original story w/Photo

    Wednesday Jul 22 | Medical News Today

    A class of drugs used to treat diabetes may be associated with protection against Parkinson's disease , according to research published this week in PLOS Medicine . The study, conducted by Dr. Ruth Brauer, of the London School of Hygiene & Tropical Medicine, found a lower incidence of PD among people using a glitazone drug to treat diabetes when compared to people who had used different treatments for diabetes.

    Comment?

  16. Common Diabetes Meds Tied to Lower Risk for Parkinson'sRead the original story w/Photo

    Tuesday Jul 21 | MedlinePlus

    A class of diabetes meds that include widely used drugs such as Actos and Avandia may help protect users against Parkinson's disease, a new study suggests. The study included nearly 44,600 British diabetes patients who took what are known as glitazone drugs -- Avandia's generic name is rosiglitazone, while pioglitazone is the generic name for Actos.

    Comment?

  17. Study Refutes Notion That Diabetes Drug Actos Raises Bladder Cancer RiskRead the original story w/Photo

    Tuesday Jul 21 | MedlinePlus

    Despite smaller, prior studies suggesting that the diabetes drug Actos might raise users' risk of bladder cancer, a large new study finds no evidence for such an effect. However, the study did find an association between the use of Actos and a rise in the risk of pancreatic cancer, although experts say it's too early to draw any conclusive link.

    Comment?

  18. Study Provides Evidence Against Pioglitazone-Bladder Cancer LinkRead the original story

    Tuesday Jul 21 | Journal Watch

    Use of the diabetes drug pioglitazone does not appear to be associated with increased bladder cancer risk, but risk for other cancers might be elevated, according to a prospective JAMA study. Researchers used a diabetes registry to identify nearly 200,000 adults aged 40 and over who were diagnosed with diabetes.

    Comment?

  19. Diabetes drug may prevent Parkinson'sRead the original story w/Photo

    Tuesday Jul 21 | NEWS.com.au

    FEW are aware they are sharing Las Vegas' main commercial airport with a classified airline that holds the US government's biggest secrets. THEY'RE rolling in cash and often showered with acclaim, but celebrities have to put up with something most us never encounter.

    Comment?

  20. Prevent Parkinson's Prognosis: Drug Previously Known To Treat...Read the original story

    Tuesday Jul 21 | Medical Daily

    Researchers at the London School of Hygiene and Tropical Medicine have discovered a happy accident: A class of drugs typically used to treat diabetes could also reduce the risk of Parkinson's disease in its users. The drugs have since been tested more to uncover their potential for treating Parkinson's, and the findings of the study have been published in the journal PLOS Medicine.

    Comment?